AR042532A1 - Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-ona - Google Patents
Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-onaInfo
- Publication number
- AR042532A1 AR042532A1 ARP030104711A ARP030104711A AR042532A1 AR 042532 A1 AR042532 A1 AR 042532A1 AR P030104711 A ARP030104711 A AR P030104711A AR P030104711 A ARP030104711 A AR P030104711A AR 042532 A1 AR042532 A1 AR 042532A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- cycloalkyl
- nr21r22
- heterocycle
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 23
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 101100173726 Arabidopsis thaliana OR23 gene Proteins 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43496902P | 2002-12-20 | 2002-12-20 | |
| US51361503P | 2003-10-23 | 2003-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042532A1 true AR042532A1 (es) | 2005-06-22 |
Family
ID=32685355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104711A AR042532A1 (es) | 2002-12-20 | 2003-12-18 | Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-ona |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7098332B2 (enExample) |
| EP (1) | EP1581531B1 (enExample) |
| JP (1) | JP2006511563A (enExample) |
| KR (1) | KR100763298B1 (enExample) |
| AR (1) | AR042532A1 (enExample) |
| AT (1) | ATE387445T1 (enExample) |
| AU (1) | AU2003294830B2 (enExample) |
| BR (1) | BR0317480A (enExample) |
| CA (1) | CA2508951A1 (enExample) |
| DE (1) | DE60319430T2 (enExample) |
| ES (1) | ES2300639T3 (enExample) |
| MX (1) | MXPA05006437A (enExample) |
| PL (1) | PL377661A1 (enExample) |
| RU (1) | RU2345077C2 (enExample) |
| WO (1) | WO2004056822A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| WO2005105801A1 (en) * | 2004-05-04 | 2005-11-10 | Warner-Lambert Company Llc | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋキナーゼインヒビターおよびそれらの使用 |
| JP2009537520A (ja) * | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法 |
| CA2663401C (en) * | 2006-09-15 | 2011-07-12 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN105683188B (zh) * | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| MA38393B1 (fr) * | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| WO2016027781A1 (ja) | 2014-08-18 | 2016-02-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体の塩およびその結晶 |
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN114984013A (zh) | 2015-03-25 | 2022-09-02 | 国立癌症研究中心 | 胆管癌治疗剂 |
| US9802917B2 (en) * | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| AU2016374441B2 (en) | 2015-12-17 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN110914267B (zh) * | 2017-07-19 | 2022-07-12 | 江苏奥赛康药业有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
| BR112020017922A2 (pt) | 2018-03-28 | 2020-12-22 | Eisai R&D Management Co., Ltd. | Agente terapêutico para carcinoma hepatocelular |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US12077534B2 (en) | 2018-12-27 | 2024-09-03 | Les Laboratoires Servier | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| US20230048132A1 (en) * | 2018-12-28 | 2023-02-16 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| AR119046A1 (es) * | 2019-05-31 | 2021-11-17 | Agios Pharmaceuticals Inc | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112062770A (zh) * | 2020-08-21 | 2020-12-11 | 台州学院 | 一种稠环二氢吡啶酮的制备方法 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI971953A7 (fi) * | 1994-11-14 | 1997-05-12 | Warner Lambert Co | Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| AU7622698A (en) | 1996-12-05 | 1998-06-29 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| PL347432A1 (en) | 1998-10-23 | 2002-04-08 | Hoffmann La Roche | Bicyclic nitrogen heterocycles |
| ATE254117T1 (de) | 1999-03-16 | 2003-11-15 | Shell Int Research | Verfahren zur reinigung von propylen-oxid |
| AR030053A1 (es) | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| JP2004505974A (ja) | 2000-08-04 | 2004-02-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法 |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| ATE497603T1 (de) * | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
-
2003
- 2003-12-08 US US10/731,594 patent/US7098332B2/en not_active Expired - Fee Related
- 2003-12-11 AT AT03785789T patent/ATE387445T1/de not_active IP Right Cessation
- 2003-12-11 AU AU2003294830A patent/AU2003294830B2/en not_active Expired - Fee Related
- 2003-12-11 RU RU2005122901/04A patent/RU2345077C2/ru not_active IP Right Cessation
- 2003-12-11 CA CA002508951A patent/CA2508951A1/en not_active Abandoned
- 2003-12-11 EP EP03785789A patent/EP1581531B1/en not_active Expired - Lifetime
- 2003-12-11 PL PL377661A patent/PL377661A1/pl not_active Application Discontinuation
- 2003-12-11 BR BR0317480-8A patent/BR0317480A/pt not_active IP Right Cessation
- 2003-12-11 WO PCT/EP2003/014067 patent/WO2004056822A1/en not_active Ceased
- 2003-12-11 ES ES03785789T patent/ES2300639T3/es not_active Expired - Lifetime
- 2003-12-11 KR KR1020057011681A patent/KR100763298B1/ko not_active Expired - Fee Related
- 2003-12-11 DE DE60319430T patent/DE60319430T2/de not_active Expired - Lifetime
- 2003-12-11 JP JP2004561276A patent/JP2006511563A/ja active Pending
- 2003-12-11 MX MXPA05006437A patent/MXPA05006437A/es active IP Right Grant
- 2003-12-18 AR ARP030104711A patent/AR042532A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1581531A1 (en) | 2005-10-05 |
| WO2004056822A1 (en) | 2004-07-08 |
| JP2006511563A (ja) | 2006-04-06 |
| EP1581531B1 (en) | 2008-02-27 |
| DE60319430D1 (de) | 2008-04-10 |
| ATE387445T1 (de) | 2008-03-15 |
| US7098332B2 (en) | 2006-08-29 |
| RU2345077C2 (ru) | 2009-01-27 |
| AU2003294830B2 (en) | 2009-06-11 |
| RU2005122901A (ru) | 2006-02-27 |
| BR0317480A (pt) | 2005-11-16 |
| DE60319430T2 (de) | 2009-02-26 |
| KR100763298B1 (ko) | 2007-10-04 |
| ES2300639T3 (es) | 2008-06-16 |
| AU2003294830A1 (en) | 2004-07-14 |
| PL377661A1 (pl) | 2006-02-06 |
| MXPA05006437A (es) | 2005-08-19 |
| CA2508951A1 (en) | 2004-07-08 |
| KR20050088202A (ko) | 2005-09-02 |
| US20040122029A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| MXPA04009435A (es) | Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico. | |
| CO6220966A2 (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| AR032605A1 (es) | Derivados (tiona) aminoquinazolinona sustituidos o sales de los mismos, compuestos intermedios de los mismos, y controladores de plagas y un metodo para utilizacion de los mismos | |
| AR119046A1 (es) | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer | |
| CO5590924A2 (es) | Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6 | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR041133A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina | |
| AR049263A1 (es) | Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer | |
| ECSP066447A (es) | Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| ES2393824T3 (es) | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus | |
| AR017189A1 (es) | Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento | |
| PE20060504A1 (es) | Derivados de pirimidina en el tratamiento de cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |